Zilovertamab Vedotin + R-CHP in untreated DLBCL

A Randomized, Open-label, Multisite, Phase 3 Study of Zilovertamab Vedotin (MK2140) in Combination With R-CHP versus R-CHOP in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL) (waveLINE-010)

Disease Types: Lymphoma

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

A Randomized, Open-label, Multisite, Phase 3 Study of Zilovertamab Vedotin (MK2140) in Combination With R-CHP versus R-CHOP in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL) (waveLINE-010)

For More Information:

https://clinicaltrials.gov/study/NCT06717347?term=waveLINE-010&rank=1